Discovering novel phenotype-selective neurotrophic factors to treat neurodegenerative diseases.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Progress in Brain Research

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/S0079-6123(03)46012-3PMID 14699964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Catechol-O-methyltransferase genotype and susceptibility to Parkinson's disease in Japan

  2005cited by this paper
• Striatal increase of neurotrophic factors as a mechanism of nicotine protection in experimental parkinsonism

  2005cited by this paper
• Platelet-derived growth factor promotes survival of rat and human mesencephalic dopaminergic neurons in culture

  2004cited by this paper
• Production of dopaminergic neurons for cell therapy in the treatment of Parkinson's disease.

  2003cited by this paper
• MANF: a new mesencephalic, astrocyte-derived neurotrophic factor with selectivity for dopaminergic neurons.

  2003influential reference
• Human α-synuclein-harboring familial Parkinson's disease-linked Ala-53 → Thr mutation causes neurodegenerative disease with α-synuclein aggregation in transgenic mice

  2002cited by this paper
• Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model

  2002cited by this paper
• High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells.

  2002influential reference
• Control of Synaptic Strength by Glial TNFα

  2002cited by this paper
• Astroglia induce neurogenesis from adult neural stem cells

  2002cited by this paper
• Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53 --> Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice.

  2002cited by this paper
• The GDNF family: Signalling, biological functions and therapeutic value

  2002influential reference
• Control of synaptic strength by glial TNFalpha.

  2002cited by this paper
• Opportunities for the use of lentiviral vectors in human gene therapy.

  2002cited by this paper
• Ciliary neurotrophic factor activates spinal cord astrocytes, stimulating their production and release of fibroblast growth factor-2, to increase motor neuron survival.

  2002cited by this paper
• Control of synapse number by glia.

  2001cited by this paper
• Selective dopaminergic vulnerability: 3,4-dihydroxyphenylacetaldehyde targets mitochondria.

  2001cited by this paper
• 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis.

  2001cited by this paper
• Glia‐derived signals induce synapse formation in neurones of the rat central nervous system

  2001cited by this paper
• GDNF and neurturin are target-derived factors essential for cranial parasympathetic neuron development.

  2001cited by this paper
• Sonic Hedgehog Facilitates Dopamine Differentiation in the Presence of a Mesencephalic Glial Cell Line

  2001cited by this paper
• Dynamic signaling between astrocytes and neurons.

  2001cited by this paper
• Target-Derived Neurotrophic Factors Regulate the Death of Developing Forebrain Neurons after a Change in their Trophic Requirements

  2001cited by this paper
• N-Acetylcysteine enhances production of dopaminergic neurons from mesencephalic-derived precursor cells

  2001cited by this paper
• Neuroprotective peptide drug delivery and development: potential new therapeutics.

  2001cited by this paper
• Target‐derived BDNF (brain‐derived neurotrophic factor) is essential for the survival of developing neurons in the isthmo‐optic nucleus

  2001cited by this paper
• Design and solution structure of functional peptide mimetics of nerve growth factor.

  2000cited by this paper
• Embryonic stem cells go dopaminergic.

  2000cited by this paper
• Neurotrophin small-molecule mimetics.

  2000cited by this paper
• Neuroglial networks: neurons and glia talk to each other.

  2000cited by this paper
• Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase

  2000cited by this paper
• Separation and identification of peptides from gel-isolated membrane proteins using a microfabricated device for combined capillary electrophoresis/nanoelectrospray mass spectrometry.

  2000cited by this paper
• Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease.

  2000cited by this paper
• Smartbombs and cloaking devices

  1999cited by this paper
• Induction of a midbrain dopaminergic phenotype in Nurr1-overexpressing neural stem cells by type 1 astrocytes

  1999cited by this paper
• Vascular, glial and neuronal effects of vascular endothelial growth factor in mesencephalic explant cultures.

  1999cited by this paper
• Transplantation of expanded mesencephalic precursors leads to recovery in parkinsonian rats

  1998cited by this paper
• Reduction in brain‐derived neurotrophic factor protein level in the hippocampal CA1 dendritic field precedes the delayed neuronal damage in the rat brain

  1998cited by this paper
• Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor

  1998cited by this paper
• Modulation of synaptic efficacy and synaptic depression by glial cells at the frog neuromuscular junction.

  1998cited by this paper
• [Neurturin: a relative of glial-cell-line-derived neurotrophic factor].

  1998cited by this paper
• Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex.

  1998cited by this paper
• Gene-Toxin Interaction as a Putative Risk Factor for Parkinson’s Disease with Dementia

  1998cited by this paper
• Reply to “Survival of expanded dopaminergic precursors is critical for clinical trials”

  1998cited by this paper
• Low frequency of α‐synuclein mutations in familial Parkinson's disease

  1998cited by this paper
• The next frontier of molecular medicine: Delivery of therapeutics

  1998cited by this paper
• Modulation of Neuronal Activity by Glial Cells in the Retina

  1998cited by this paper
• P450 enzymes and Parkinson's disease: The story so far

  1998cited by this paper
• Astrocyte-mediated potentiation of inhibitory synaptic transmission

  1998cited by this paper
• BDNF gene transcripts in mesencephalic neurons and its differential regulation by NMDA

  1998cited by this paper
• Neurotrophic molecules: strategies for designing effective therapeutic molecules in neurodegeneration.

  1998cited by this paper
• An immortalized, type-1 astrocyte of mescencephalic origin source of a dopaminergic neurotrophic factor

  1998cited by this paper
• Relations between heterogeneity of dopamine transporter binding and function and the behavioral pharmacology of cocaine.

  1997cited by this paper
• Serotonin, dopamine and norepinephrine transporter mRNAs: heterogeneity of distribution and response to 'binge' cocaine administration.

  1997cited by this paper
• Ciliary Neurotrophic Factor Activates JAK/Stat Signal Transduction Cascade and Induces Transcriptional Expression of Glial Fibrillary Acidic Protein in Glial Cells

  1997cited by this paper
• Dopaminergic Neurons Intrinsic to the Primate Striatum

  1997cited by this paper
• Defects of cytochrome c oxidase in the substantia nigra of Parkinson's disease: An immunohistochemical and morphometric study

  1997cited by this paper
• Cerebellar microcomplexes.

  1997cited by this paper
• Characterization of femtomole levels of proteins in solution using rapid proteolysis and nanoelectrospray ionization mass spectrometry

  1997cited by this paper
• Selective dopamine neurotoxicity by an industrial chemical: an environmental cause of Parkinson's disease?

  1997cited by this paper
• Evaluation of four candidate genes encoding proteins of the dopamine pathway in familial and sporadic Parkinson's disease

  1997cited by this paper
• Isolation, cloning and characterization of a putative type-1 astrocyte cell line.

  1997cited by this paper
• Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease.

  1997cited by this paper
• Secretion of GDNF by glial cells does not account for the neurotrophic effect of bFGF on dopamine neurons in vitro.

  1996cited by this paper
• A gene from human chromosomal band 3p21.1 encodes a highly conserved arginine-rich protein and is mutated in renal cell carcinomas.

  1996cited by this paper
• Different signalling pathways involved in transforming growth factor-beta 1-induced morphological change and type IV collagen synthesis in simian virus-40-immortalized normal human salivary gland duct and myoepithelial cell clones.

  1996cited by this paper
• Standardized methods to bioassay neurotrophic factors for dopaminergic neurons.

  1996cited by this paper
• Substantia nigra pars reticulata neurons in Parkinson's disease.

  1996cited by this paper
• Evidence for a novel neurotrophic factor for dopaminergic neurons secreted from mesencephalic glial cell lines

  1996cited by this paper
• A femtomolar-acting neuroprotective peptide.

  1996cited by this paper
• Neurturin, a relative of glial-cell-line-derived neurotrophic factor

  1996cited by this paper
• Paracrine and autocrine actions of neurotrophic factors

  1996cited by this paper
• Screening of interleukins for survival-promoting effects on cultured mesencephalic dopaminergic neurons from embryonic rat brain.

  1995cited by this paper
• Astroglia demonstrate regional differences in their ability to maintain primary dendritic outgrowth from mouse cortical neurons in vitro.

  1995cited by this paper
• Plasticity of nerve afferents to nigrostriatal neurons in parkinson's disease

  1995cited by this paper
• Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls.

  1995cited by this paper
• Fibroblast growth factors: Structure-activity on dopamine neurons in vitro

  1995cited by this paper
• Convergent signalling in the action of integrins, neuropeptides, growth factors and oncogenes.

  1995cited by this paper
• Calbindin-D28k-containing neurons in the human hypothalamus: relationship to dopaminergic neurons.

  1995cited by this paper
• Dopamine denervation, age of onset, and Parkinson's disease

  1995cited by this paper
• Intrathecal baclofen–a multicentre clinical comparison of the Medtronics Programmable, Cordis Secor and Constant Infusion Infusaid drug delivery systems

  1995cited by this paper
• Neurotrophic factors as therapeutic agents in amyotrophic lateral sclerosis. Potential and pitfalls.

  1995cited by this paper
• Mesencephalic type 1 astrocytes rescue dopaminergic neurons from death induced by serum deprivation

  1994influential reference
• Neuroprotective effects of TGF-beta 1.

  1994cited by this paper
• Genetic analysis of indefinite division in human cells: evidence for a common immortalizing mechanism in T and B lymphoid cell lines.

  1994cited by this paper
• TGF beta 2 and TGF beta 3 are potent survival factors for midbrain dopaminergic neurons.

  1994cited by this paper
• Parkinsonian serum carries complement-dependent toxicity for rat mesencephalic dopaminergic neurons in culture.

  1994cited by this paper
• Low dopamine transporter mRNA levels in midbrain regions containing calbindin.

  1994cited by this paper
• Transport of Human Recombinant Brain-Derived Neurotrophic Factor (BDNF) Through the Rat Blood−Brain Barrier in Vivo Using Vector-Mediated Peptide Drug Delivery

  1994cited by this paper
• Retention of basic fibroblast growth factor immunoreactivity in dopaminergic neurons of the substantia nigra during normal aging in humans contrasts with loss in Parkinson's disease.

  1994cited by this paper
• The neurotrophins NT-4/5 and BDNF augment serotonin, dopamine, and GABAergic systems during behaviorally effective infusions to the substantia nigra.

  1994cited by this paper
• Neurotrophic factors: an evolutionary perspective.

  1994cited by this paper
• Transforming growth factor-beta promotes survival of midbrain dopaminergic neurons and protects them against N-methyl-4-phenylpyridinium ion toxicity.

  1994cited by this paper
• Nigral type I astrocytes release a soluble factor that increases dopaminergic neuron survival through mechanisms distinct from basic fibroblast growth factor.

  1994cited by this paper
• TGFβ2 and TGFβ3 are potent survival factors for midbrain dopaminergic neurons

  1994cited by this paper
• GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons.

  1993cited by this paper
• Interleukin‐2 Modulates Evoked Release of [3H]Dopamine in Rat Cultured Mesencephalic Cells

  1993cited by this paper
• Differential effects of platelet-derived growth factor isoforms on dopamine neurons in vivo: -BB supports cell survival, -AA enhances fiber formation.

  1993cited by this paper
• Trophic actions of transforming growth factor alpha on mesencephalic dopaminergic neurons developing in culture.

  1993cited by this paper
• Deprenyl increases survival of rat foetal nigral neurones in culture.

  1993cited by this paper

• Functional characteristics, intercellular interactions and pathophysiological associations of astrocytes in Parkinson’s disease

  2025cites this paper
• Transcranial photobiomodulation therapy with 808 nm light changes expression of genes and proteins associated with neuroprotection, neuroinflammation, oxidative stress, and Alzheimer’s disease: Whole RNA sequencing of mouse cortex and hippocampus

  2025cites this paper
• Astrocytes in Parkinson’s Disease: From Role to Possible Intervention

  2023cites this paper
• S100a16 Deficiency Prevents Alcohol-induced Fatty Liver Injury via Inducing MANF Expression in Mice

  2023cites this paper
• MANF: an emerging therapeutic target for metabolic diseases.

  2022cites this paper
• MANF: A Novel Endoplasmic Reticulum Stress Response Protein—The Role in Neurological and Metabolic Disorders

  2021cites this paper
• Peptide LIQ promotes cell protection against zinc-induced cytotoxicity through microtubule stabilization.

  2020cites this paper
• Engrafted primary type-2 astrocytes improve the recovery of the nigrostriatal pathway in a rat model of Parkinson's disease

  2020cites this paper
• Health Benefits of Endurance Training: Implications of the Brain-Derived Neurotrophic Factor—A Systematic Review

  2019cites this paper
• Optimal control with MANF treatment of photoreceptor degeneration.

  2019cites this paper
• Expression and Distribution of Mesencephalic Astrocyte-Derived Neurotrophic Factor in the Retina and Optic Nerve

  2017cites this paper
• Neurodegenerative signaling factors and mechanisms in Parkinson's pathology.

  2017cites this paper
• The Proform of Glia Cell Line-Derived Neurotrophic Factor: a Potentially Biologically Active Protein

  2014cites this paper
• Gene therapy with AAV2-CDNF provides functional benefits in a rat model of Parkinson's disease

  2013cites this paper
• A Review of MANF Literature : Implications for the Development Program of Amarantus Bioscience Holdings Inc . ( Status Q 2 / 2013 ) Prepared

  2013cites this paper
• MANF regulates dopaminergic neuron development in larval zebrafish.

  2012cites this paper
• Extracellular cysteine (Cys)/cystine (CySS) redox regulates metabotropic glutamate receptor 5 activity.

  2012cites this paper
• Neuroglial Plasticity at Striatal Glutamatergic Synapses in Parkinson's Disease

  2011cites this paper
• Adult human brain cell culture for neuroscience research.

  2010cites this paper
• Astrocytes and therapeutics for Parkinson’s disease

  2010cites this paper
• Nanotechnology applications and approaches for neuroregeneration and drug delivery to the central nervous system

  2010cites this paper
• Neurotrophic factor therapy for Parkinson's disease.

  2010cites this paper
• TGF-β in Dopamine Neuron Development, Maintenance and Neuroprotection

  2009cites this paper
• TGF-beta in dopamine neuron development, maintenance and neuroprotection.

  2009cites this paper
• Mesencephalic Astrocyte-Derived Neurotrophic Factor Is Neurorestorative in Rat Model of Parkinson's Disease

  2009cites this paper
• Mesencephalic Astrocyte-Derived Neurotrophic Factor Is an Ischemia-Inducible Secreted Endoplasmic Reticulum Stress Response Protein in the Heart

  2008cites this paper
• Natalie Gude , Mark A . Sussman and Christopher C . Glembotski Archana Tadimalla

  2008cites this paper
• Triptolide Upregulates NGF Synthesis in Rat Astrocyte Cultures

  2007cites this paper
• Estradiol regulation of astroglia and apolipoprotein E: an important role in neuronal regeneration.

  2007cites this paper
• Neuroglia in the inferior olivary nucleus during normal aging and Alzheimer's disease

  2006cites this paper
• Dynamics of neural stem cell-mediated neuroprotection in the presence of oxidative stress: studies in vitro and in vivo

  2006cites this paper
• Mesencephalic astrocyte-derived neurotrophic factor enhances nigral &ggr;-aminobutyric acid release

  2006cites this paper
• Neuroprotective Therapy in Parkinson Disease

  2006cites this paper
• Metallothionein reduces central nervous system inflammation, neurodegeneration, and cell death following kainic acid‐induced epileptic seizures

  2005cites this paper
• Nanotechnology approaches for the regeneration and neuroprotection of the central nervous system.

  2005cites this paper
• Transient and Widespread Astroglial Activation in the Brain after a Striatal 6-Ohda-Induced Partial Lesion of the Nigrostriatal System

  2005cites this paper
• A Femtomolar Acting Octapeptide Interacts with Tubulin and Protects Astrocytes against Zinc Intoxication*

  2004cites this paper